BRPI0600285C1 - compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas - Google Patents
compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticasInfo
- Publication number
- BRPI0600285C1 BRPI0600285C1 BRC10600285-4A BRPI0600285A BRPI0600285C1 BR PI0600285 C1 BRPI0600285 C1 BR PI0600285C1 BR PI0600285 A BRPI0600285 A BR PI0600285A BR PI0600285 C1 BRPI0600285 C1 BR PI0600285C1
- Authority
- BR
- Brazil
- Prior art keywords
- lipid
- analogs
- pharmaceutical compounds
- nanostructures
- paclitaxel
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000037803 restenosis Diseases 0.000 title abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 5
- 239000002086 nanomaterial Substances 0.000 abstract 3
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract 1
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 abstract 1
- 230000031018 biological processes and functions Effects 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 239000002047 solid lipid nanoparticle Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
COMPOSTOS FARMACêUTICOS CONTENDO NANOPARTìCULAS úTEIS PARA TRATAMENTO DE LESõES REESTENóTICAS. São descritas compostos farmacêuticos contendo nanoestruturas lipídicas carreadoras de rapamicina ou análogos, paclitaxel ou análogos, ou a combinação de rapamicina ou análogos e paclitaxel ou análogos úteis para a estabilização (não progressão) ou redução da placa ateromatosa e para a prevenção e tratamento da reestenose intra-stent, assim como de outras doenças e processos biológicos caracterizados pela proliferação celular aumentada e/ou desordenada, sendo as nanoestrutu ras lipídicas selecionadas dentre lipoproteinas LDL e/ou VLDL associadas ou não a componentes lipídicos compatíveis com a administração intravenosa como fosfatidilcolina, fosfolipideos, lecitinas, colesterol e seus ésteres, e triacilgliceróis, em que as lipoproteinas plasmáticas são livres, acetiladas ou oxidadas. Essas nanoestruturas lipídicas compreendem nanoemu Isões, lipossomas de dimensões nanométricas, carreadores lipídicos nanoestruturados, nanopartículas lipídicas sólidas, e/ou similares.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRC10600285-4A BRPI0600285C1 (pt) | 2006-01-13 | 2006-01-13 | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
| CNA2007800017443A CN101365447A (zh) | 2006-01-13 | 2007-01-12 | 用于治疗再狭窄病变的含有纳米粒子的药物组合物 |
| JP2008549721A JP2009523133A (ja) | 2006-01-13 | 2007-01-12 | 再狭窄病変治療に有用なナノ粒子含有の薬化合物類 |
| PCT/BR2007/000015 WO2007079560A2 (en) | 2006-01-13 | 2007-01-12 | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
| CA002636336A CA2636336A1 (en) | 2006-01-13 | 2007-01-12 | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
| AU2007204550A AU2007204550A1 (en) | 2006-01-13 | 2007-01-12 | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions |
| EP07701600A EP1978957A4 (en) | 2006-01-13 | 2007-01-12 | NANOTEILS CONTAINING PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF RESTENOTIC LESIONS |
| US12/217,028 US20090011005A1 (en) | 2006-01-13 | 2008-07-01 | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRC10600285-4A BRPI0600285C1 (pt) | 2006-01-13 | 2006-01-13 | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0600285A BRPI0600285A (pt) | 2007-10-02 |
| BRPI0600285C1 true BRPI0600285C1 (pt) | 2011-10-11 |
Family
ID=38256650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRC10600285-4A BRPI0600285C1 (pt) | 2006-01-13 | 2006-01-13 | compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090011005A1 (pt) |
| EP (1) | EP1978957A4 (pt) |
| JP (1) | JP2009523133A (pt) |
| CN (1) | CN101365447A (pt) |
| AU (1) | AU2007204550A1 (pt) |
| BR (1) | BRPI0600285C1 (pt) |
| CA (1) | CA2636336A1 (pt) |
| WO (1) | WO2007079560A2 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| EP2241342A3 (en) * | 2006-11-20 | 2011-01-12 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| JP5824511B2 (ja) | 2010-05-03 | 2015-11-25 | テイコク ファーマ ユーエスエー インコーポレーテッド | 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法 |
| KR101314579B1 (ko) * | 2011-04-07 | 2013-10-10 | 광주과학기술원 | 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법 |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| CN114028623B (zh) * | 2021-10-26 | 2024-02-27 | 江苏朴芃医疗科技有限公司 | 心脏分流器 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
| EE200000693A (et) * | 1998-05-20 | 2002-04-15 | The Liposome Company, Inc. | Uudsed makroosakeste formulatsioonid |
| US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US20030065382A1 (en) * | 2001-10-02 | 2003-04-03 | Fischell Robert E. | Means and method for the treatment of coronary artery obstructions |
| US20050095267A1 (en) * | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
| CN102697737B (zh) * | 2003-04-03 | 2014-03-19 | 杰西.L.-S.奥 | 负载肿瘤靶向药物的颗粒 |
| CN1791386A (zh) * | 2003-05-19 | 2006-06-21 | 巴克斯特国际公司 | 抗癫痫和抗痴呆药物以及免疫抑制剂的小－颗粒药物制剂 |
| US8043631B2 (en) * | 2004-04-02 | 2011-10-25 | Au Jessie L S | Tumor targeting drug-loaded particles |
| AU2005326322B2 (en) * | 2004-07-01 | 2009-02-05 | Yale University | Targeted and high density drug loaded polymeric materials |
| US7727554B2 (en) * | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
| JP2008533204A (ja) * | 2005-03-21 | 2008-08-21 | マクサイト， インコーポレイテッド | 病気又は症状の治療のためのドラッグ送達システム |
-
2006
- 2006-01-13 BR BRC10600285-4A patent/BRPI0600285C1/pt active Search and Examination
-
2007
- 2007-01-12 WO PCT/BR2007/000015 patent/WO2007079560A2/en not_active Ceased
- 2007-01-12 CA CA002636336A patent/CA2636336A1/en not_active Abandoned
- 2007-01-12 EP EP07701600A patent/EP1978957A4/en not_active Withdrawn
- 2007-01-12 JP JP2008549721A patent/JP2009523133A/ja active Pending
- 2007-01-12 CN CNA2007800017443A patent/CN101365447A/zh active Pending
- 2007-01-12 AU AU2007204550A patent/AU2007204550A1/en not_active Abandoned
-
2008
- 2008-07-01 US US12/217,028 patent/US20090011005A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007079560A2 (en) | 2007-07-19 |
| CA2636336A1 (en) | 2007-07-19 |
| AU2007204550A1 (en) | 2007-07-19 |
| CN101365447A (zh) | 2009-02-11 |
| BRPI0600285A (pt) | 2007-10-02 |
| JP2009523133A (ja) | 2009-06-18 |
| US20090011005A1 (en) | 2009-01-08 |
| EP1978957A4 (en) | 2013-01-09 |
| WO2007079560A3 (en) | 2007-12-27 |
| EP1978957A2 (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Ultrasound-activated piezo-hot carriers trigger tandem catalysis coordinating cuproptosis-like bacterial death against implant infections | |
| Chen et al. | Antibacterial micelles with vancomycin-mediated targeting and pH/lipase-triggered release of antibiotics | |
| Joseph et al. | Cationic pillararenes potently inhibit biofilm formation without affecting bacterial growth and viability | |
| Zhao et al. | Synergy of non-antibiotic drugs and pyrimidinethiol on gold nanoparticles against superbugs | |
| Galbadage et al. | Molecular nanomachines disrupt bacterial cell wall, increasing sensitivity of extensively drug-resistant Klebsiella pneumoniae to meropenem | |
| Moszczyńska et al. | Non-thermal plasma application in medicine—Focus on reactive species involvement | |
| Wang et al. | Redox active Zn@ MOFs as spontaneous reactive oxygen species releasing antimicrobials | |
| Martínez-Gutierrez et al. | Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles | |
| Liu et al. | Graphene oxide attenuates the cytotoxicity and mutagenicity of PCB 52 via activation of genuine autophagy | |
| CO7190240A2 (es) | Sistema para tratar infecciones pulmonares | |
| Bohanon et al. | Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis | |
| WO2007079560A3 (en) | Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions | |
| PT2153260T (pt) | Composição que compreende uma alta concentração de moléculas biologicamente ativas e processos de preparação da mesma | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| Guan et al. | Targeting mitochondria with natural polyphenols for treating Neurodegenerative Diseases: a comprehensive scoping review from oxidative stress perspective | |
| Singh et al. | MoS2-modified curcumin nanostructures: the novel theranostic hybrid having potent antibacterial and antibiofilm activities against multidrug-resistant hypervirulent klebsiella pneumoniae | |
| BRPI1010028A2 (pt) | métodos de tratamento de encefalopatia hepática | |
| Sadasivan et al. | Acute NMDA toxicity in cultured rat cerebellar granule neurons is accompanied by autophagy induction and late onset autophagic cell death phenotype | |
| Zhong et al. | Development of amphiphilic coumarin derivatives as membrane-active antimicrobial agents with potent in vivo efficacy against Gram-positive pathogenic bacteria | |
| Chavez-Dozal et al. | In vitro analysis of flufenamic acid activity against Candida albicans biofilms | |
| BRPI0519890A2 (pt) | macrociclos de 18 elementos e seus análogos | |
| Theofilopoulos et al. | Liver X receptors and cholesterol metabolism: role in ventral midbrain development and neurodegeneration | |
| Guan et al. | 2, 5-Hexanedione induces autophagic death of VSC4. 1 cells via a PI3K/Akt/mTOR pathway | |
| Gu et al. | Dihydroartemisinin-loaded chitosan nanoparticles inhibit the rifampicin-resistant mycobacterium tuberculosis by disrupting the cell wall | |
| Marangoni et al. | Membrane cholesterol modulates superwarfarin toxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B11Q | Dismissal: the certificate of addition was not accessory to any patent, or a patent which was nominated accessory and no longer exists |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |